University of California, San Francisco (Fresno)
Hematology and Oncology fellowship · Fresno, CA · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is University of California, San Francisco's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About University of California, San Franciscoinstitution-wide hematology and oncology research
Hematology and Oncology publications from University of California, San Francisco and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
620
works per year
3rd of 74 hematology and oncology fellowship programs
-4.0%
2-year growth
64th of 74 hematology and oncology fellowship programs
34.0%
in top 10% of field (works before 2025)
3rd of 72 hematology and oncology fellowship programs
53.0%
cited above world average
5th of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 2,235Hematology · 760
Hematology and Oncology research topics at University of California, San Francisco
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 333
- CAR-T cell therapy research 250
- Multiple Myeloma Research and Treatments 224
- Cancer survivorship and care 202
- Glioma Diagnosis and Treatment 195
- Pancreatic and Hepatic Oncology Research 161
- Acute Myeloid Leukemia Research 137
- Global Cancer Incidence and Screening 125
Most cited at University of California, San Francisco since 2024
All hematology and oncology papers there on OpenAlex
- GliomaMichael Weller et al. · Nature Reviews Disease Primers · 2024 · PubMed · cited 650
- Embracing cancer complexity: Hallmarks of systemic diseaseCharles Swanton et al. · Cell · 2024 · PubMed · cited 555
- The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023Lisa M Force et al. · The Lancet · 2025 · PubMed · cited 498
- Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in OncologyAl B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 406
- NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024Al B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 312
- Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaClaire Roddie et al. · New England Journal of Medicine · 2024 · PubMed · cited 256
- Membrane transporters in drug development and as determinants of precision medicineAleksandra Galetin et al. · Nature Reviews Drug Discovery · 2024 · PubMed · cited 246
- Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyJaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network · 2025 · PubMed · cited 243
- FOXO1 is a master regulator of memory programming in CAR T cellsAlexander E. Doan et al. · Nature · 2024 · PubMed · cited 237
- Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy OutcomesPriya Rastogi et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 236